Bicycle Therapeutics Plc
BCYC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.65
KIRA · Stoqly’s AI analyst, in plain words
- Bicycle Therapeutics Plc had $72.6M of revenue in fiscal 2025, up 105.8% on the year before. Over five years, revenue changed +47.5% a year on average.
- Its operating margin was −340.4%, up 254.6 pts: of every 100 in sales, about −340 is left after running the business.
- Bicycle Therapeutics Plc lost $219M in fiscal 2025.
- Free cash flow was −$252M in fiscal 2025, −347.2% of revenue.
Market cap
$255M
P/E
—
Revenue
$72.6M
Net income
−$219M
Free cash flow
−$252M
Operating margin
−340.4%
Bicycle Therapeutics Plc in 30 seconds · fiscal 2025
Are sales growing?
+105.8%
Yes. Sales grew 105.8% last year.
Does it make a profit?
−301.7%
No. It lost money last year.
Does profit turn into cash?
−347.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Bicycle Therapeutics Plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- BICYCLE THERAPEUTICS PLC
- CIK
- 0001761612
Bicycle Therapeutics Plc · BCYC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $11.7M | $14.5M | $27.0M | $35.3M | $72.6M |
| Revenue growth | 12.6% | 23.6% | 86.5% | 30.8% | 105.8% |
| Operating margin | −561.0% | −806.6% | −704.1% | −595.0% | −340.4% |
| Net income | −$66.8M | −$113M | −$181M | −$169M | −$219M |
| Net margin | −571.2% | −779.3% | −669.7% | −479.2% | −301.7% |
| Diluted EPS | −$2.67 | −$3.80 | −$5.08 | −$2.90 | −$3.16 |
| Cash | |||||
| Cash from operations | −$14.8M | −$86.1M | −$60.6M | −$165M | −$250M |
| Capital expenditure | $2.0M | $19.0M | $2.9M | $1.2M | $2.4M |
| Free cash flow | −$16.8M | −$105M | −$63.6M | −$166M | −$252M |
| FCF margin | −143.8% | −726.7% | −235.6% | −470.5% | −347.2% |
| Share count change | 30.9% | 18.4% | 20.0% | 63.5% | 19.0% |
| Debt and strength | |||||
| Cash and short-term investments | $439M | $339M | $526M | $880M | $628M |
| Debt incl. finance leases | $29.9M | $30.3M | $30.7M | — | — |
| Shareholders' equity | $346M | $271M | $371M | $793M | $610M |
| Current ratio | 12.7x | 6.9x | 8.1x | 13.8x | 12.0x |
| Interest coverage | −22.0x | −34.9x | −58.2x | −121.3x | −1,199.3x |
| Returns and quality | |||||
| Return on equity | −30.3% | −36.5% | −56.3% | −29.0% | −31.2% |
| Return on tangible equity | −19.3% | −41.6% | −48.7% | −21.3% | −35.9% |
| Piotroski F-score | 4 | 2 | 4 | 3 | 1 |
| Altman Z'' | 6.1 | 2.5 | 2.2 | 7.2 | 5.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.5M
8 insiders
Of sales under plans
13%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bicycle Therapeutics Plc · BCYC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.65 a share, the company is worth $255M.
Source: SEC EDGAR XBRL filings (CIK 0001761612). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.